| Literature DB >> 27206767 |
Navin K Verma1, M H U Turabe Fazil2, Seow Theng Ong2, Madhavi Latha S Chalasani2, Jian Hui Low2, Amuthavalli Kottaiswamy2, Praseetha P2, Atish Kizhakeyil2, Sunil Kumar3, Aditya K Panda4, Michael Freeley5, Sinead M Smith6, Bernhard O Boehm2, Dermot Kelleher7.
Abstract
In this study, we report that the integrin LFA-1 cross-linking with its ligand ICAM-1 in human PBMCs or CD4(+) T cells promotes Th1 polarization by upregulating IFN-γ secretion and T-bet expression. LFA-1 stimulation in PBMCs, CD4(+) T cells, or the T cell line HuT78 activates the Notch pathway by nuclear translocation of cleaved Notch1 intracellular domain (NICD) and upregulation of target molecules Hey1 and Hes1. Blocking LFA-1 by a neutralizing Ab or specific inhibition of Notch1 by a γ-secretase inhibitor substantially inhibits LFA-1/ICAM-1-mediated activation of Notch signaling. We further demonstrate that the Notch pathway activation is dependent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3β (GSK3β), which is mediated via Akt and ERK. Furthermore, in silico analysis in combination with coimmunoprecipitation assays show an interaction between NICD and GSK3β. Thus, there exists a molecular cross-talk between LFA-1 and Notch1 through the Akt/ERK-GSK3β signaling axis that ultimately enhances T cell differentiation toward Th1. Although clinical use of LFA-1 antagonists is limited by toxicity related to immunosuppression, these findings support the concept that Notch inhibitors could be attractive for prevention or treatment of Th1-related immunologic disorders and have implications at the level of local inflammatory responses.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27206767 DOI: 10.4049/jimmunol.1501264
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422